ADVERTISEMENT

United Kingdom

England: NICE Finds Its Advice Can Cut Drug Appraisal Times By Three Months

The health technology assessment institute said its “unique insights” could help companies effectively prepare for their appraisals, potentially streamlining their path through the process, and helping to get innovative technologies to patients faster.

UK Kicks Off Seven-Week Pre-Market Regulatory Consultation

A short consultation has been launched by the UK MHRA on elements of devices regulation for Great Britain that have evolved since the first consultation on UKCA marking in 2021.

BGMA Names Accord’s Carter To Lead Women’s Networking Group

Setting out plans to support career development and create learning and networking opportunities for women in the UK generics and biosimilars industry, local off-patent association the BGMA has named Accord’s Clara Carter as chair of a new women’s networking group.

Apixaban Prices Begin To Correct After Months Of UK Rises

After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.

UK’s NHS Bets Big On Teva’s Champix Generic

The UK’s National Health Service is set to roll out Teva’s varenicline smoking-cessation daily tablet to “tens of thousands” of smokers in England.

UK Toolkit To Accelerate Research Set-Up Across England, NI, Scotland And Wales

The Health Research Authority says its new toolkit explains the differences and similarities in the research approval and set-up processes across the four UK nations so that researchers and sponsors are clear on what they need to do if they want to conduct a study in more than one of the countries.

UK MHRA Plans Revised Device Roadmap By End Of 2024

The milestones on MHRA’s in-progress medtech regulatory roadmap for Great Britain will be subject to some change in the coming months.

Lytenava: England Becomes First to Fund Ophthalmic Bevacizumab For Wet AMD

Up to 40,000 people could be set to access Outlook Therapeutics’ Lytenava in England, according to health technology assessment institute NICE, which found the drug for wet age-related macular degeneration had similar health benefits to aflibercept and ranibizumab, and similar costs to aflibercept.

Medtechs Applaud UK Life Sciences Fund But Seek Lowering Of £8M Project Threshold

The Life Sciences Innovative Manufacturing Fund, set out in the UK budget last month, is live for applications. More UK medtechs would benefit if the cost threshold were scaled down, the industry argues.

Hospital Equipment Spending Gets A Boost In UK Budget

UK chancellor of the exchequer Rachel Reeves said her 2024 budget announcement would address the problem of ‘hospitals being without the equipment they need.’